ArticleClinical and translational medicine2020
Noninvasive prediction of response to cancer therapy using promoter profiling of circulating cell-free DNA.
Article in Clinical and translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Assessing circulating tumour DNA (ctDNA) as a prognostic biomarker in locally advanced rectal cancer: a systematic review and meta-analysis.International journal of colorectal disease · 2024Pooled it
- Circulating tumour DNA as biomarker for rectal cancer: A systematic review and meta-analyses.Frontiers in oncology · 2023Pooled it
- Genome-wide nucleosome footprints of plasma cfDNA predict preterm birth: A case-control study.PLoS medicine · 2025Article
- Saliva as a Diagnostic Tool for Systemic Diseases-A Narrative Review.Medicina (Kaunas, Lithuania) · 2025Review
- Plasma Cell-Free DNA Concentration and Fragmentomes Predict Neoadjuvant Chemotherapy Response in Cervical Cancer Patients.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Promoter profiles in plasma CfDNA exhibits a potential utility of predicting the efficacy of neoadjuvant chemotherapy in breast cancer patients.Breast cancer research : BCR · 2024Article
- Evaluation of ctDNA in the Prediction of Response to Neoadjuvant Therapy and Prognosis in Locally Advanced Rectal Cancer Patients: A Prospective Study.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Noninvasive prediction of axillary lymph node status in breast cancer using promoter profiling of circulating cell-free DNA.Journal of translational medicine · 2022Article
- A Deep-Learning Pipeline for TSS Coverage Imputation From Shallow Cell-Free DNA Sequencing.Frontiers in medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.